Albertsons CompaniesACI
ACI logo
Fair Value
US$20.94
Share price15 Jun
US$14.7629.5% undervalued intrinsic discount
Loading
1Y-33.36%
7D4.46%

ACI: Digital Integration And Customer Engagement Will Drive Outperformance Beyond 2025

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
12 Jan 25
Updated
15 Jun 26
Views
473
Not Invested

Last Update 15 Jun 26

ACI: Cost Discipline And Buybacks Will Support Returns Despite Sector Caution

Analysts have reduced their average price target on Albertsons Companies by $1 to $19. This reflects updated views on sector conditions and company specific drivers, while core model assumptions such as fair value and profit margin remain essentially unchanged.

Analyst Commentary

Recent Street Research on Albertsons Companies points to a mixed setup, with several firms trimming price targets and at least one earlier increase. The tone of the commentary clusters around how execution, regulatory risk and deal outcomes could affect what investors are willing to pay for the stock.

Bullish Takeaways

  • Bullish analysts who previously raised the target to US$20 from US$19 appear comfortable that the current business model can support that valuation level, assuming steady execution on margins and cash flow.
  • The decision by some firms to keep ratings unchanged while adjusting targets suggests that, in their view, Albertsons still fits within an acceptable risk and return profile at or near current levels.
  • The relatively small size of several target changes, often around US$1 per share, points to incremental adjustments to valuation frameworks rather than a wholesale shift in opinion on the company’s long term earnings power.
  • Maintaining coverage with formal price targets, even when reduced, signals that analysts continue to see Albertsons as relevant for investors who are focused on consistent operations and disciplined capital allocation.

Bearish Takeaways

  • Bearish analysts have lowered price targets across multiple firms, which indicates growing caution around how much upside they see in the stock relative to execution risks and sector conditions.
  • The removal of Albertsons from JPMorgan’s Analyst Focus List points to reduced conviction that the stock stands out versus other opportunities, even if the rating itself is not detailed here.
  • Larger target cuts at some brokers, including reductions of up to US$4 per share, suggest that certain analysts are rethinking assumptions on valuation multiples or potential deal outcomes.
  • The cluster of recent target reductions highlights concerns that near term drivers may not fully support prior expectations on growth, margin resilience or balance sheet flexibility, leading to more conservative fair value estimates.

What's in the News

  • Albertsons introduced a patent pending Intelligent Quality Control tool that uses Google Cloud’s Gemini Enterprise and computer vision to support produce inspections in select distribution centers, with early results pointing to more consistent ratings, faster decisions, and expanded quality data across initial categories such as strawberries and grapes. Source: Company announcement
  • Albertsons Media Collective rolled out onsite incrementality measurement to help advertisers assess the causal impact of onsite display media on sales using test and control frameworks, with case study results for S. Martinelli & Co. indicating a $7.45 iROAS, 65% new to brand buyers, and a 33% lift in sales for a recent campaign. Source: Albertsons Media Collective
  • Baron & Budd announced a finalized US$774m nationwide settlement agreement with Albertsons tied to allegations about the company’s role in the opioid epidemic, with proceeds directed to states, counties, municipalities, and Native American tribes as part of broader national recoveries exceeding US$60b across multiple defendants. Source: Baron & Budd
  • The Board of Directors declared a first quarter fiscal 2026 cash dividend of US$0.17 per share, described as an annualized US$0.68 per share, and the company outlined an equity buyback authorization of US$2.0b, up from US$900m remaining under the prior plan, alongside commentary about confidence in the core business and free cash flow. Source: Company announcement
  • The U.S. Food and Drug Administration issued an enforcement report on a voluntary Class II recall of 12,222 tubs of Lucerne 2% Cottage Cheese distributed by Albertsons, citing potential metal fragments in product with a “BEST BEFORE MAR 31 2026” code and distribution across AK, ID, CA, OR, and WA. Source: U.S. FDA enforcement report

Valuation Changes

  • Fair Value: Model fair value remains unchanged at $20.94 per share, indicating no revision to the core valuation output.
  • Discount Rate: The discount rate has fallen slightly, from 10.08% to 9.86%, which makes future cash flows marginally more valuable in the model.
  • Revenue Growth: The long term revenue growth assumption is essentially flat, remaining at 0.73% with no meaningful directional signal.
  • Net Profit Margin: The modeled net profit margin is effectively unchanged at 1.19%, with no adjustment that alters the overall profitability assumptions.
  • Future P/E: The future P/E multiple has edged down slightly from 10.92x to 10.85x, reflecting a small reduction in how much investors might be modeled as paying for each dollar of future earnings.
14 viewsusers have viewed this narrative update

Key Takeaways

  • Growth in digital channels, health offerings, and loyalty programs is enhancing customer engagement, retention, and overall sales momentum.
  • Technology upgrades, private label expansion, and omnichannel integration are strengthening margins, operational efficiency, and competitive positioning.
  • Margin and earnings growth are pressured by lagging e-commerce, rising labor costs, pharmacy mix headwinds, stiff competition, and slow realization of cost-saving initiatives.

Catalysts

About Albertsons Companies
    Through its subsidiaries, operates in the food and drug retail industry in the United States.
What are the underlying business or industry changes driving this perspective?
  • Accelerating growth in digital channels-including a 25% surge in e-commerce sales and a robust loyalty program-strongly positions Albertsons to capitalize on rising consumer demand for convenience and online grocery ordering, supporting higher future revenue and customer retention.
  • Expansion and integration of pharmacy and health offerings (20% YoY growth), with enhanced digital cross-shopping, is increasing customer engagement, driving more frequent visits, and boosting overall basket size, directly benefiting top-line sales and increasing customer lifetime value.
  • Modernization through technology investments-such as automation, AI-driven inventory/pricing, and centralized buying-are streamlining operations, reducing labor and supply chain costs, and positioning the company for long-term margin expansion and improved net earnings.
  • Increasing penetration of private label and own brands (now at 25.7% of sales with a push to reach 30%+), along with targeted value investments, are driving higher-margin sales, deepening brand loyalty, and contributing to gross margin stabilization over time.
  • Leveraging omnichannel capabilities and integrated digital experiences is enabling Albertsons to better compete for market share amidst urbanization and evolving health and wellness trends, which supports sustained same-store sales growth and overall top-line momentum.
Albertsons Companies Earnings and Revenue Growth

Albertsons Companies Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Albertsons Companies's revenue will remain fairly flat over the next 3 years.
  • Analysts assume that profit margins will increase from 0.3% today to 1.2% in 3 years time.
  • Analysts expect earnings to reach $1.0 billion (and earnings per share of $2.42) by about June 2029, up from $217.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.2 billion in earnings, and the most bearish expecting $910.8 million.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 10.9x on those 2029 earnings, down from 33.8x today. This future PE is lower than the current PE for the US Consumer Retailing industry at 20.0x.
  • Analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 9.86%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Albertsons' e-commerce business, though growing at 25% year-over-year, still lags industry peers in penetration, and reaching breakeven profitability remains a challenge; a persistent gap or inability to scale digital efficiently could result in continued pressure on net margins and limit overall earnings growth.
  • Rising labor costs and ongoing union contract negotiations, as evidenced by 120,000 associates potentially affected in FY25 and a focus on improved wages and benefits, pose long-term risks of margin compression and higher SG&A expense, which could negatively impact net income.
  • The grocery industry's highly competitive landscape-marked by sustained price investments, heavy promotional activity, and mounting pressure from mass, club, and discount value players (as well as non-traditional entrants like Amazon and Dollar General)-threatens to erode Albertsons' pricing power and market share, squeezing revenue growth and profitability.
  • Growth is increasingly driven by the pharmacy segment (notably from high-priced GLP-1 drugs) rather than core grocery sales, but pharmacy often carries lower profitability and creates sustained mix headwinds for gross margin; over-reliance on this trend exposes future revenue and margin risk if pharmacy growth normalizes or reimbursement rates tighten.
  • Despite technology and productivity investments, the company's near-term gross margin is under pressure as savings from supply chain efficiencies and national buying only gradually materialize, while aggressive investment in price and customer value is required to support unit growth; this mismatch could delay or dampen EBITDA and earnings growth in the face of inflation and secular consumer shifts towards value and healthier specialty foods.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $20.94 for Albertsons Companies based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $26.0, and the most bearish reporting a price target of just $14.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $85.0 billion, earnings will come to $1.0 billion, and it would be trading on a PE ratio of 10.9x, assuming you use a discount rate of 9.9%.
  • Given the current share price of $14.86, the analyst price target of $20.94 is 29.0% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Albertsons Companies?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$20.94
vs US$14.7629.5% undervalued intrinsic discount
PastFuture-502m85b20162018202020222024202620282029Revenue US$85.0bEarnings US$1.0b
0.7%
Revenue growth
1.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Albertsons Companies

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Moderate risk with reasonable growth potential.

Market capUS$7.2b
PB3.9x
Estimated Growth0.6%
Dividend Yield4.6%
Full analysis

CEO & management

Susan Morris
CEO
4.8yrs
CEO Tenure

Through its subsidiaries, operates in the food and drug retail industry in the United States.